CRIS Current Research Information System

ZACCHERINI, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.771
NA - Nord America 5.573
EU - Europa 3.516
SA - Sud America 401
Continente sconosciuto - Info sul continente non disponibili 362
AF - Africa 292
OC - Oceania 9
Totale 16.924
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.411
VN - Vietnam 2.483
SG - Singapore 1.466
CN - Cina 1.287
IT - Italia 1.118
HK - Hong Kong 523
GB - Regno Unito 458
SE - Svezia 414
DE - Germania 352
BR - Brasile 262
FR - Francia 215
IN - India 213
BD - Bangladesh 174
NL - Olanda 169
KR - Corea 167
FI - Finlandia 144
RU - Federazione Russa 111
IE - Irlanda 108
JP - Giappone 102
CA - Canada 85
CH - Svizzera 78
CI - Costa d'Avorio 78
TG - Togo 76
BG - Bulgaria 69
PH - Filippine 57
ZA - Sudafrica 55
AR - Argentina 50
JO - Giordania 46
AT - Austria 45
UA - Ucraina 43
MX - Messico 42
ES - Italia 41
ID - Indonesia 34
TH - Thailandia 33
PL - Polonia 31
IQ - Iraq 30
EC - Ecuador 27
EE - Estonia 24
BE - Belgio 21
PK - Pakistan 21
CO - Colombia 20
TR - Turchia 20
SC - Seychelles 19
SA - Arabia Saudita 18
IR - Iran 16
TW - Taiwan 15
CL - Cile 13
HR - Croazia 13
VE - Venezuela 13
EG - Egitto 12
JM - Giamaica 12
LT - Lituania 11
MY - Malesia 11
UZ - Uzbekistan 11
NG - Nigeria 10
NP - Nepal 10
CZ - Repubblica Ceca 8
HU - Ungheria 8
CR - Costa Rica 7
AL - Albania 6
KE - Kenya 6
PY - Paraguay 6
RO - Romania 6
RS - Serbia 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
AU - Australia 5
CD - Congo 5
DZ - Algeria 5
MA - Marocco 5
PE - Perù 5
LV - Lettonia 4
NZ - Nuova Zelanda 4
TT - Trinidad e Tobago 4
AM - Armenia 3
GR - Grecia 3
IL - Israele 3
MU - Mauritius 3
NI - Nicaragua 3
OM - Oman 3
PS - Palestinian Territory 3
PT - Portogallo 3
SN - Senegal 3
UY - Uruguay 3
AZ - Azerbaigian 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
GH - Ghana 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
MD - Moldavia 2
MG - Madagascar 2
PR - Porto Rico 2
SY - Repubblica araba siriana 2
VA - Santa Sede (Città del Vaticano) 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
Totale 16.547
Salva come PNG Salva come JPEG
Città #
Singapore 1.052
Ashburn 654
Ho Chi Minh City 539
Hanoi 499
Hong Kong 469
San Jose 393
Southend 357
Dong Ket 340
Fairfield 336
Chandler 325
Hefei 308
Santa Clara 239
Bologna 231
Los Angeles 175
Houston 161
Council Bluffs 159
Woodbridge 158
Beijing 141
Seoul 141
Wilmington 133
Boardman 125
Seattle 125
Cambridge 121
Milan 116
Da Nang 113
Helsinki 112
Princeton 112
Dallas 109
Dublin 106
Ann Arbor 105
New York 105
Tokyo 82
Lauterbourg 81
Abidjan 78
Lomé 76
Sofia 68
Bern 65
Haiphong 56
Rome 49
São Paulo 49
Frankfurt am Main 47
Amman 45
Munich 39
Guangzhou 37
Buffalo 36
Bengaluru 35
Berlin 35
Nanjing 33
Westminster 33
Biên Hòa 32
Redondo Beach 32
Nuremberg 31
San Diego 30
Shenyang 29
Jinan 28
Padova 28
Hải Dương 27
Toronto 27
Turin 27
London 26
Orem 26
Vienna 26
Florence 25
Shanghai 24
Amsterdam 23
Can Tho 23
Zhengzhou 23
Johannesburg 22
Jakarta 21
Rimini 21
Vũng Tàu 21
Warsaw 21
Phoenix 20
Chicago 19
Naples 19
Thái Nguyên 19
Tianjin 19
Lappeenranta 18
Mexico City 18
Bangkok 17
Des Moines 17
Redmond 17
Chennai 16
Denver 16
Hebei 16
Ninh Bình 16
Bến Tre 15
Changsha 15
Hangzhou 15
Saint Petersburg 15
Xi'an 15
Atlanta 14
Brooklyn 14
Brussels 14
Falkenstein 14
Modena 14
Montreal 14
Paris 14
San Francisco 14
Turku 14
Totale 10.044
Salva come PNG Salva come JPEG
Nome #
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 485
Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study 434
OS-077 Single-cell RNA sequencing of peripheral blood mononuclear cells in patients with acutely decompensated cirrhosis reveals a specific monocyte subset associated with an increased risk of progression to ACLF 388
Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study 365
Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment 331
Validation and expansion of Baveno VII recompensation criteria in patients with cirrhosis and curable liver disease 290
Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF 281
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial 270
Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients 269
Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register 266
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 263
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 256
Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register 248
Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications 248
Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids 244
A case of pneumonia and sepsis in cirrhosis as paradigm of the problems in the management of bacterial infections in cirrhosis and of the limitations of current knowledge 237
Statins, ACE/ARBs drug use, and risk of pneumonia in hospitalized older patients: a retrospective cohort study 224
Low haemoglobin level predicts early hospital readmission in patients with cirrhosis and acute decompensation 224
On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites 217
Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET) 216
Mortality rate and risk factors for gastrointestinal bleeding in elderly patients 216
Albumin administration in internal medicine: A journey between effectiveness and futility 214
Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register 212
Real-word experience of long-term albumin treatment in a large cohort of patients with cirrhosis and ascites (Real-Answer study) 210
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis 210
Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure 210
Outcomes of patients with alcohol-related cirrhosis referred to a hepatology outpatient clinic 207
A case of prolonged cholestatic hepatitis induced by azithromycin in a young woman 195
Patients with cirrhosis and ascites treated with long-term albumin: An integrated management proposal based on a real-life study 192
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial 192
The analysis of food intake in patients with cirrhosis waiting for liver transplantation: A neglected step in the nutritional assessment 191
Prognostic value of degree and types of anaemia on clinical outcomes for hospitalised older patients 190
Real-world experience with long-term albumin in patients with cirrhosis and ascites 190
Need for deprescribing in hospital elderly patients discharged with a limited life expectancy: The REPOSI study 190
Incidence and clinical implications of abstinence-induced hepatic recompensation in decompensated alcohol-related cirrhosis 188
The Role of Transjugular Intrahepatic Portosystemic Shunt for the Management of Ascites in Patients with Decompensated Cirrhosis 188
A Case of Immune-Mediated Liver Injury Induced by Olaparib 185
Assessing the role of amino acids in systemic inflammation and organ failure in patients with {ACLF} 185
Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. 181
Role of human albumin in the management of complications of liver cirrhosis. 180
Acute-on-chronic liver failure is a distinct syndrome developing in patients with acute dcompensation of cirrhosis. 180
Predictors of clinical trajectories of patients with acutely decompensated cirrhosis. An external validation of the PREDICT study 179
QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? 177
How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. 175
Disorders of albumin metabolism in liver diseases. 175
PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis 173
Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbab le, gut-restricted adsorbent in models and patients with cirrhosis 171
Development and validation of a prognostic score to predict mortality in patients with acute on chronic liver failure. 170
Clinical trajectories of patients with cirrhosis and ascites receiving long-term albumin. A proposal for a personalized management based on real-world experience 168
Human albumin in the management of complications of cirrhosis. 167
Human albumin in the management of complications of liver cirrhosis. 165
Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation 163
Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis 162
Outcome of hepatic resection for HCC in ideal and non-ideal candidates 161
Predictors of clinical trajectories in patients admitted for acutely decompensated cirrhosis: An external validation of the PREDICT study 160
Predictors of clinical courses in patients wih acutely decompensated cirrhosis. An external validation of the PREDICT study 157
Hyposplenism as a cause of pneumococcal meningoencephalitis in an adult patient with coeliac disease 152
Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant 151
A web-based group treatment for patients with alcoholic liver diseases at the time of the COVID-19 pandemic 148
The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology 146
Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis 145
Albumin Administration is Efficacious in the Management of Patients with Cirrhosis: A Systematic Review of the Literature 145
Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial 144
Approach and management of dysnatremias in cirrhosis 142
Long‐term albumin improves the outcomes of patients with decompensated cirrhosis and diabetes mellitus: Post hoc analysis of the ANSWER trial 141
Reversal of liver fibrosis by the antagonism of endocannabinoid CB1-receptor in a rat model of CCl4-induced advanced cirrhosis. 141
null 138
Albumin: Indications in chronic liver disease 138
Pattern of in-hospital changes in drug use in the older people from 2010 to 2016 137
Management of ascites in patients with cirrhosis: An update 134
Simvastatin plus Rifaximin to prevent ACLF in patients with decompensated cirrhosis. A randomised, double-blind, placebo-controlled, phase-3 trial: the liverhope efficacy trial 133
Prolonged albumin administration in patients with decompensated cirrhosis: the amount makes the difference 131
Defining aging phenotypes and related outcomes: Clues to recognize frailty in hospitalized older patients 130
Pro: The Role of Albumin in Pre–Liver Transplant Management 130
The Use of Rifaximin in Patients With Cirrhosis 129
Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease 121
Living alone as an independent predictor of prolonged length of hospital stay and non-home discharge in older patients 118
Management of cirrhotic patients with ascites. 118
Correction and Prevention of Hyponatremia in Patients With Cirrhosis and Ascites: Post Hoc Analysis of the ANSWER Study Database 117
Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium 113
Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects 110
Managing Multiorgan Failure in Acute on Chronic Liver Failure 108
Unmet needs in hepatology: The guidance of the Italian association for the study of the liver (AISF) 106
Albumin in hospitalized patients with complications of cirrhosis: Not a suit for all seasons 102
Prevention of cirrhosis complications: Looking for potential disease modifying agents 100
Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. 97
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis 97
null 88
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study 81
The role and indications of albumin in advanced liver disease 77
null 59
Correction to ‘Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF’ [J Hepatol 2020 (72) 688–701] (Journal of Hepatology (2020) 72(4) (688–701), (S0168827819306968), (10.1016/j.jhep.2019.11.009)) 58
Personalised Long‐Term Albumin Treatment Based on Three‐Month Ascites Response in Patients With Decompensated Cirrhosis 57
Long-term albumin treatment for decompensated cirrhosis in Italy: A propensity score-matched, retrospective, real-world chart analysis 53
Pediatric Liver and Kidney Transplant Recipients Demonstrate Greater Serological Response to SARS-CoV-2 Vaccination Than Adults 42
PD-L1 and the risk of bacterial infection in patients with chronic liver diseases: An international multicohort study 31
Pre‐Treatment Serum Albumin Concentration Predicts Clinical Benefit of Long‐Term Albumin in Patients With Cirrhosis and Ascites 24
null 3
null 3
null 1
Totale 16.924
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.844
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.844
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.233 0 27 63 84 118 80 35 142 56 74 403 151
2022/20231.415 111 220 77 140 94 114 42 91 235 44 120 127
2023/2024679 32 72 53 80 38 132 31 45 19 36 95 46
2024/20252.460 107 358 207 203 316 138 122 95 96 209 168 441
2025/20267.941 762 611 575 558 607 335 1.532 255 1.301 578 372 455
2026/2027690 252 438 0 0 0 0 0 0 0 0 0 0
Totale 16.924